New Study Shows Common Osteoporosis Drugs May Lower Dementia Risk
A recent study suggests that some widely used medications for osteoporosis could help reduce the risk of Alzheimer’s disease and other forms of dementia in older adults. The research involved over 121,000 adults aged 60 and above, revealing that those who took nitrogen-containing bisphosphonates (NBPs) had a 16% lower chance of developing Alzheimer’s and similar conditions compared to those who did not use these medications. Moreover, the risk was found to be 24% lower when compared to patients on different osteoporosis treatments.
Nitrogen-containing bisphosphonates are medications designed to slow down bone loss and minimize fracture risks, particularly in people with osteoporosis. Some common examples include alendronate, ibandronate, risedronate, and zoledronate.
Osteoporosis leads to weakened bones that are more susceptible to fractures, a condition that predominantly affects older individuals. The participants in this study, conducted in Hong Kong, were all diagnosed with osteoporosis or had experienced significant fractures. Importantly, none of them had taken osteoporosis medications prior to the study.
According to Ching-Lung Cheung, an associate professor at the University of Hong Kong, there appears to be a connection between bone health and brain health. Prior research indicates that individuals with low bone density or osteoporosis are more likely to face dementia later in life. This emphasizes the importance of maintaining strong bones, which might also reduce the risk of cognitive decline.
However, the researchers caution that these findings do not definitively prove that bisphosphonate use decreases dementia risk; further clinical trials are needed to confirm this theory. Additionally, the study’s scope was limited to a Chinese population, raising questions about whether the findings would apply to other groups.
Another limitation noted by the researchers was the lack of initial cognitive testing. This could mean that participants who already had signs of cognitive decline were less likely to receive osteoporosis treatment, which may have affected the study results. Furthermore, the researchers lacked details on the severity of osteoporosis and fractures among participants, as well as information about their intake of over-the-counter calcium and vitamin D.
The study also acknowledged that other external factors—such as education level, social isolation, air pollution, and vision loss—could also influence dementia risk.
While the results suggest that older individuals taking NBPs for osteoporosis might see lower rates of Alzheimer’s and related dementias, they do not yet warrant prescribing these drugs solely for dementia prevention. The authors of the study advocate for more inclusive research to explore further, including the potential impact of gender on dementia risk.
Cheung emphasized the necessity of conducting clinical trials to validate these observational findings. If confirmed, it could have significant implications for dementia care. The goal is to encourage patients and healthcare providers to consider the overall benefits and risks of treatments like bisphosphonates.
Overall, these findings highlight a promising avenue for future research in the intersection of bone health and cognitive function.
